Hinduja Hospital

PD Hinduja Hospital and Medical Group. Mumbai, India
www.hindujahospital.com

Academic teaching hospital
Chest clinic at Hinduja Hospital known authority on drug-susceptible and multidrug-resistant TB and played a significant role in identifying totally-drug-resistant TB
MDR-TB cohort is wide demographic of TB patients in Mumbai
CIDI partnership developing a clinical cohort and database of patients help understand MDR-TB, working on whole genome sequencing, novel TB diagnostics and developing clinical trials using novel drugs also planned

Logistical Information for Field Study at PD Hinduja Hospital

Studies/Projects
Publications

The Regional Prospective Observational Research In Tuberculosis (Report) India Phase II Common Protocol

Post Date:

2022-01-10

Countries:

Clinical Sites:

Purpose and Scientific Aims The purpose of the RePORT India Phase II Common Protocol is to collect and utilize data and specimens for tuberculosis (TB) research, leveraging the existing infrastructure, processes, and scientific partnerships established under RePORT India consortium. The RePORT...

Pharmacokinetic Assessment of MDR-TB Drugs in the Treatment of TB Meningitis

Post Date:

2020-08-23

Countries:

Clinical Sites:

Rationale: MDR-TBM is a devastating disease with high mortality and severe neurologic sequelae among survivors. We recognize the importance of sufficient drug concentrations at the site of infection for efficacy of anti-TB drugs and believe it is likely that drug distribution into brain and CSF...

Validation of Sputum as Direct DNA Source for Whole Genome Sequencing of Mycobacterium Tuberculosis

Post Date:

2018-09-20

Countries:

India

Clinical Sites:

Hinduja Hospital

This study was terminated on September 27, 2021 Dr. Jeffrey Tornheim is Principal Investigator for this study. There are limited studies available from India on whole genome sequencing (WGS). This is a first-of-its-kind wherein WGS for MTB will be carried out utilizing direct sputum DNA and...

Predictors of Resistance Emergence Evaluation in Multidrug Resistant-Tuberculosis Patients on Treatment (PREEMPT Pilot Study)

Post Date:

2018-03-20

Countries:

Clinical Sites:

Indo-JHU Clinical Resarch Partnership is participating with Brazilian colleagues in a 3-year effort led by Boston University to identify what contributes to TB drug resistance.

MDR-TB Free: Monitoring Adverse Effects, Utilizing Resources Optimally, Knowing Resistance Patterns, and Treatment Strategy

Post Date:

2017-03-24

Countries:

India

Clinical Sites:

BJGMC

Hinduja Hospital

This study is also known as MDR-TB MUKT: Monitoring Adverse Effects, Utilizing Resources Optimally, Knowing Resistance Patterns, and Treatment Strategy. Purpose: To establish an observational cohort of MDR-TB cases and household contacts with accompanying biorepository at PD Hinduja National...

Establishing an Observational Cohort Database for Patient Care and Research at the Hinduja Hospital Chest Clinic

Post Date:

2016-08-30

Countries:

India

Clinical Sites:

Hinduja Hospital

India has the largest burden of global tuberculosis (TB), accounting for one quarter of the total number of cases reported. Together with South Africa, India sees one-third of the total number of deaths from TB. Drug-resistant strains of the disease are also on the rise, with India having one...

Whole Genome Sequencing and Trek Sensititre Testing of Stored Isolates of Drug-resistant Tuberculosis from a Clinical Cohort at Hinduja Hospital, Mumbai

Post Date:

2016-05-02

Countries:

India

Clinical Sites:

Hinduja Hospital

Among HIV-positive TB patients presenting to Médecins San Frontières (MSF) clinics in Mumbai, 78% carried MDR-TB strains, with nearly half also found to have additional drug resistance. A previously published cohort of 202 patients cared for at these MSF clinics have enrolled in a...

ART Study 1: Database: Epidemiology of HIV/AIDS and Associated Comorbidities in a Public Antiretroviral Treatment (ART) Clinic at BJGMC in Pune

Post Date:

2014-06-14

Countries:

India

Clinical Sites:

BJGMC

Hinduja Hospital

Since 2004, the National AIDS Control Program of India has been rolling out free antiretroviral therapy. Byramjee Jeejeebhoy Government Medical College (BJGMC), located in Pune, India, is now the largest HIV clinic in India, with over 26,000 adult and pediatric patients registered since 2005...

Tuberculosis Noon Conference

Post Date:

2013-10-24

Countries:

Clinical Sites:

This effort ended in 2015. As part of the BJGMC-Johns Hopkins India Fogarty Training Program, from 2013-2015 CCGHE hosted the live Tuberculosis Noon Conference webcast. Led by Drs. Maunank Shah, Jonathan Golub, and Richard Chaisson, these webcast meetings brought together Johns Hopkins TB...

RePORT India

Post Date:

2012-06-30

Countries:

Clinical Sites:

RePORT India is a joint venture between the Indian and US governments. The Indo-US Vaccine Action Program, a collaboration between the Indian Department of Biotechnology (DBT), the Indian Council of Medical Research (ICMR), and the US NIH, is co-funding six teams of India- and US-based...

Delamanid central nervous system pharmacokinetics in tuberculous meningitis in rabbits and humans

Post Date:

2019-09-23

Clinical Sites:

Hinduja Hospital

Publication:

Antimicrobial Agents and Chemotherapy

Central nervous system tuberculosis (TB) is devastating and affects vulnerable populations. Multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculous meningitis (TBM) specifically are nearly uniformly fatal, with little information being available to guide the treatment of...

Re: A Shorter Regimen for Rifampin-Resistant Tuberculosis

Post Date:

2019-09-12

Countries:

India

Clinical Sites:

Hinduja Hospital

Publication:

New England Journal of Medicine

Dr. Jeff Tornheim and colleagues respond to an NEJM article about shorter course TB treatment.

Few eligible for the newly recommended short course MDR-TB regimen at a large Mumbai private clinic

Post Date:

2019-01-28

Countries:

India

Clinical Sites:

Hinduja Hospital

Publication:

BMC Infectious Diseases

BACKGROUND: India has the world's highest tuberculosis burden, and Mumbai is particularly affected by multidrug resistant tuberculosis (MDR-TB). WHO recommends short, intensive treatment ("Short Course") for previously untreated pulmonary MDR-TB patients but does not require universal...

Multiplex-PCR to detect pAmpC β-lactamases among Enterobacteriaceae at a tertiary care laboratory in Mumbai, India

Post Date:

2018-12-13

Countries:

India

Clinical Sites:

Hinduja Hospital

Publication:

Microbiology

Drug-resistance due to AmpC β-lactamases represents a growing problem worldwide. In this study, a previously collected sample of 108 cefoxitin-resistant clinical isolates was assessed for AmpC β-lactamase production through routine phenotypic testing and double-disc cefoxitin/cloxcallin (DD-CC),...

Pyrosequencing to resolve discrepant Xpert MTB/RIF and Mycobacterial Growth Indicator Tube 960

Post Date:

2018-03-26

Countries:

India

Clinical Sites:

Hinduja Hospital

Publication:

Lung India

Lung India: Indo-JHU researchers find that pyrosequencing can clear up discrepancies about drug resistance in TB.